Showing Latest Articles
Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
JACC - Journal of the American College of Cardiology: Cardiovascular Interventions, 08/16/2011
Clinical Article
Ueno M et al. – Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in diabetes mellitus (DM) patients with coronary artery disease receiving dual antiplatelet therapy (DAPT).
Methods- A prospective, randomized, double–blind, parallel design study conducted in DM patients with stable coronary artery disease receiving DAPT.
- Patients were randomly assigned to either pentoxifylline 400 mg or placebo 3 times daily for 14 days.
- The PD effects were assessed by vasodilator–stimulated phosphoprotein phosphorylation assay, light transmittance aggregometry, VerifyNow P2Y12 assay (Accumetric, Inc., San Diego, California), and multiple electrode aggregometry at baseline and 14 days.
- The PD effects were also assessed according the presence or absence of high on–treatment platelet reactivity status.
- A total of 40 patients were available for analysis.
- At 14 days, there were no differences in the P2Y12 reactivity index as assessed by vasodilator–stimulated phosphoprotein phosphorylation between treatment groups (primary endpoint; p = 0.93).
- Intra–group comparisons also failed to show any differences between baseline and 14–day P2Y12 reactivity index assessment in the placebo and pentoxifylline arms (p = 0.61).
- There were no significant inter– and intra–group differences in all other PD measures.
- The PD effects did not vary according the presence or absence of high on–treatment platelet reactivity.